A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs).

Michael J. Mauro,Andreas Hochhaus,Carla Boquimpani,Yosuke Minami,Alex Allepuz,Fotis Polydoros,Véronique Bédoucha,Paola Aimone,Delphine Rea

A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs).

2019

Michael J. Mauro
Andreas Hochhaus
Carla Boquimpani
Yosuke Minami
Alex Allepuz
Fotis Polydoros
Véronique Bédoucha
Paola Aimone
Delphine Rea

TPS7070Background: There is a need for new treatment options for pts with CML who are intolerant/resistant to currently available BCR-ABL1 ATP-binding site targeted TKIs. Asciminib is a potent and ...

Keywords:

Myeloid leukemia
Pathology
Oncology
Internal medicine
Chronic phase CML
Tyrosine kinase
Bosutinib
Medicine
treatment options
in patient
previously treated

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations